Precision Neuroscience Archives - Medical Design Sourcing

5 more brain-computer interface companies you need to know

BCI technology from Cognixion, Precision Neuroscience, InBrain Neuroelectronics and Kandu Health.

The brain-computer interface (BCI) space continues to rise in notoriety, and a number of players are throwing their hats in the ring.

Such technologies could enable users to control a computer with their brain, or even go beyond that. Countless immobile people someday could control a mouse cursor, keyboard, mobile device/tablet, wheelchair or prosthetic device by only thinking.

Big names have already established their presence in the space. Elon Musk’s Neuralink continues to make headway, while Bill Gates- and Jeff Bezos-backed Synchron has an innovative catheter-delivered implant. Blackrock Neurotech, which has a next-generation BCI, has been implanting its Utah Array in patients since 2004.

Those companies and more were covered in last year’s roundup of brain-computer interface companies you need to know. But there are several more companies ou…

Precision Neuroscience wins FDA breakthrough nod for BCI, buys factory in Texas

[Image from Precision Neuroscience]Precision Neuroscience announced today that its brain-computer interface (BCI) technology won FDA breakthrough device designation.

The company also acquired a microelectromechanical systems (MEMS) foundry outside Dallas, Texas. Completed through its Precision BioMEMS subsidiary, the acquisition brings its supply chain in-house. It also establishes Precision as a leading-edge manufacturer of biomedical MEMS in the U.S., according to a news release.

Precision Neuroscience develops the Layer 7 Cortical Interface, designed with 1,024 tiny electrodes spanning an area of one square centimeter. The company embedded the electrodes in a flexible film that conforms to the brain surface. This film — one-fifth the thickness of a human hair — is designed for implantation and removal by neurosurgeons without damaging brain tissue.

The company designed it to map a large area of the brain’s surface at resolutions higher than typical neuro…

Precision Neuroscience begins first-in-human trial for brain-computer interface

[Image from Precision Neuroscience]Precision Neuroscience today announced the completion of the first-in-human procedures for a pilot clinical study of its neural implant system.

The study evaluates the company’s brain-computer interface (BCI), the Layer 7 Cortical Interface. Precision Neuroscience designed the Layer 7 with 1,024 tiny electrodes spanning an area of one square centimeter. The company embedded the electrodes in a flexible film that conforms to the brain surface. This film — one-fifth the thickness of a human hair — is designed for implantation and removal by neurosurgeons without damaging brain tissue.

Precision Neuroscience designed the device to map a large area of the brain’s surface at resolutions higher than typical neurosurgical procedures.

The study aims to record and map the brain’s activity in unprecedented detail. Precision Neuroscience partnered with West Virginia University’s Rockefeller Neuroscience Institute to…

Janssen exec discusses company’s precision neuroscience strategy and partnerships

[Aliaksandr Marko/Adobe Stock]

In mid-April, San Diego–based Pipeline Therapeutics announced a global license and development agreement with Janssen Pharmaceutica NV (NYSE:JNJ), focusing on PIPE-307, an investigational compound targeting nervous system disorders. As a pioneer in precision neuroscience, Pipeline Therapeutics aims to create targeted treatments for patients. PIPE-307, an oral, highly selective antagonist of the muscarinic M1 receptor, embodies this approach, having completed two phase 1 clinical trials and obtained FDA clearance for clinical development in relapsing-remitting multiple sclerosis (RRMS) patients. Janssen received a worldwide, exclusive license to research and develop PIPE-307 in all indications.

Under the agreement, Pipeline will receive $50 million upfront from Janssen, with the possibility of receiving an additional $25 million in equity investments from J&J and Pipeline’…

BCI developer Precision Neuroscience raises $41M Series B

[Image from Precision Neuroscience]Brain-computer interface (BCI) maker Precision Neuroscience announced today that it closed a $41 million Series B funding round.

Bloomberg first reported that the company intended to announce the financing before Precision Neuroscience confirmed it in a LinkedIn post. Forepont Capital Partners led the financing round. According to Bloomberg, it adds to a previous fundraising totaling $12 million.

Precision Neuro, co-created by a founding member of Elon Musk’s Neuralink BCI venture, has been developing its BCI since 2021. Benjamin Rapoport, a former part of the Neuralink effort, started the company with private equity investor Michael Mager.

The company described it in the LinkedIn post as “high-resolution, minimally invasive and reversible.” The BCI is placed under the skull, on top of brain tissue without penetrating it.

Precision Neuroscience said it has validated its system and obtained for more…